Clinical trials: Bladder Cancers
Overactive Bladder, Bladder Cancer
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75-85% of patients with bladder cancer present with a disease that is confined to the mucosa or submucosa.
- Conditions
- Overactive Bladder, Bladder Cancer, Synergo
- Trial name
- OABSYNERGO (NCT01955408)
- Testing
- Questionnaires, anticholinergic treatment, urodynamic study
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- Meir Medical Center
Urinary Bladder Neoplasms
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
- Trial name
- NCT03404791
- Testing
- TAR-200
- Where
- 12 sites in United States, Spain
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Bladder Cancer
Clinical Evaluation of the miR Sentinel BCa™ Test to Diagnose Bladder Cancer in Hematuria Patients
The purpose of the study is to establish the clinical performance and utility of the miR Sentinel™ BCa Test, a urine exosome-based diagnostic test, as an aid in diagnosing bladder cancer.
- Trial name
- NCT04155359
- Where
- United States
- Volunteers
- 444 people
- Sponsor
- miR Scientific LLC
Pancreatic Neoplasms Malignant, Malignant Neoplasm of Gall Bladder Non-resectable
Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers
SUMMARY PROJECT TITLE: Concurrent chemo-radiation using Tomotherapy based IMRT in locally advanced Gallbladder and Pancreatic cancers: A Phase II study SPECIFIC OBJECTIVES: Primary To assess the radiological response by dose…
- Trial name
- NCT01118897
- Testing
- Tomotherapy
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Tata Memorial Hospital
Urinary Bladder Neoplasms
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
A study comparing nivolumab and bacterial drugs given to help the body's immune system in the bladder versus bacterial drugs alone in high risk bladder cancer participants.
- Trial name
- CheckMate 7G8 (NCT04149574)
- Testing
- nivolumab, Bacillus Calmette-Guérin (BCG)
- Where
- 63 sites in United States, Argentina and 14 more
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer, Colo-rectal Cancer
Prehabilitation in High-risk Oncologic Surgery
The goal of this clinical study is to learn whether a prehabilitation program can improve recovery after major abdominal surgery in adults with cancer who are receiving treatment before surgery.
- Conditions
- Pancreatic Cancer, Colo-rectal Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT07638410
- Testing
- Multidisciplinary Prehabilitation Program
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Fox Chase Cancer Center
Cancer of Pancreas, Cancer of Liver
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma Multiforme, Multiple Myeloma, and GI…
- Conditions
- Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon
- Trial name
- NCT03607643
- Testing
- Cannabidiol, Bortezomib, Leucovorin
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Leaf Vertical Inc.
Bladder Cancer
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib may have on tumor cells.
- Trial name
- BLAST (NCT02885974)
- Testing
- Celecoxib, Gemcitabine, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Baylor College of Medicine
Bladder Neoplasm
Comparison of Interfascial Injection Versus Subpectineal Injection on Ultrasound-guided Obturator Nerve Block
This study aimed to assess the effectiveness of the ultrasound-guided interfascial injection approach with the subpectineal injection technique for obturator nerve block in bladder cancers undergoing transurethral resection of…
- Trial name
- NCT05540847
- Testing
- Interfascial Injection, Subpectineal Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Diskapi Teaching and Research Hospital
Breast Cancer, Prostate Cancer
Behavioral Weight Loss Program for Cancer Survivors in Maryland
Behavioral Weight Loss for Overweight and Obese Cancer Survivors in Maryland: A Demonstration Project
- Conditions
- Breast Cancer, Prostate Cancer, Melanoma (Skin), Endometrial Cancer
- Trial name
- ASPIRE (NCT04534309)
- Testing
- Written Weight Loss Material, Weight Loss App, Behavioral Lifestyle Weight Loss Intervention (Coaching)
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Urothelial Carcinoma of the Bladder
Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer
Invasive urothelial bladder cancer is a common malignancy causing 14,000 deaths annually in the United States. The primary objective of the feasibility/Phase I portion of the study is to establish the feasibility and safety of…
- Trial name
- NCT01520038
- Testing
- Proton therapy, IMRT
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Postoperative Ileus, Bladder Cancer
Prucalopride for Postoperative Ileus in Patients Undergoing Robot-assisted Laparoscopic Radical Cystectomy
The first purpose is to determine whether prucalopride can promote the recovery of intestinal function after robot-assisted laparoscopic radical cystectomy and urinary diversion.
- Trial name
- NCT05001763
- Testing
- Prucalopride
- Volunteers
- 160 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cervical Cancer, Lung Cancer
Internet-based System for Cancer Patients to Self-report Toxicity
Cancer patients may develop side effects during treatment, such as nausea, pain, fatigue, diarrhea, constipation, or shortness of breath.
- Conditions
- Cervical Cancer, Lung Cancer, Prostate Cancer, Vaginal Cancer
- Trial name
- NCT00578006
- Testing
- Questioners, STAR website
- Where
- United States
- Volunteers
- 1,007 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urothelial Carcinoma
BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma
BIBF1120 in patients with advanced FGFR3 mutated, FGFR3 overexpressed, or FGFR3 wild type urothelial carcinoma of urinary bladder, urethra, ureter, and renal pelvis and who have failed platinum-based chemotherapy.
- Trial name
- NCT02278978
- Testing
- BIBF1120
- Where
- Taiwan
- Volunteers
- 129 people
- Sponsor
- National Taiwan University Hospital
Bladder Cancer, Invasive Bladder Cancer
Nordic Cystectomy Study I - Neutrophil-lymphocyte Ratio (NLR)
Around 7200 cases of Muscle Invasive Bladder Cancer are diagnosed annually in the Nordic countries combined. Muscle Invasive Bladder Cancer is an aggressive disease and it is linked with high mortality rates.
- Trial name
- NorCys-NLR (NCT04523025)
- Testing
- NLR-ratio
- Where
- Finland
- Volunteers
- 230 people
- Sponsor
- Turku University Hospital
Muscle Invasive Bladder Cancer
A Novel Pathway to Detect Muscle-invasive Bladder Cancer Based on Integrated Clinical Features and VI-RADS Score on MRI
This study investigates the clinical, pathological, and radiological features, including the Vesical Imaging-Reporting and Data System (VI-RADS) score, that correlate with muscle-invasive bladder cancer (MIBC).
- Trial name
- VI-RADS (NCT06807008)
- Where
- 4 sites in Italy
- Volunteers
- 139 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Urothelial Carcinoma, Urethral Neoplasms
Cabozantinib for Advanced Urothelial Cancer
Background: Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate and ovarian tumors respond to it.
- Conditions
- Urothelial Carcinoma, Urethral Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms
- Trial name
- NCT01688999
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
T1 Urinary Bladder Cancer
Multicentric Prospective T1 Urinary Bladder Cancer Registry
Synopsis Rationale Patients with T1 urinary bladder cancer (UBC) are at high risk for recurrence and progression. However, the prognosis is dependent on several concomitant factors.
- Trial name
- ROGUE-1 (NCT05792033)
- Testing
- Prospective registry
- Where
- Austria
- Volunteers
- 700 people
- Sponsor
- Medical University of Vienna
Bladder Cancer
Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection
Phase 1 study to provide quantitative characterization of the renal elimination of ethacrynic acid and metabolites in patients with non-muscle invasive bladder cancer (NMIBC) at the time of transurethral resection of bladder tumor
- Trial name
- NCT02852564
- Testing
- Ethacrynic Acid
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Eugene Lee, MD
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.